Anna Berkenblit, Chief Scientific and Medical Officer of Pancreatic Cancer Action Network, shared a post on LinkedIn:
“Today on Capitol Hill, I joined PanCAN President and CEO Julie Fleshman and leading cancer investigators in meetings with bipartisan members of Congress to discuss current priorities in pancreatic cancer research.
We emphasized the importance of sustained federal investment in The National Institutes of Health, National Cancer Institute (NCI) and the Pancreatic Cancer Research Program (PCARP), noting that nearly 80% of pancreatic cancer research funding in the United States is federally supported. We also reviewed recent scientific advances, including emerging RAS-targeted therapeutic strategies, which represent a significant step forward in addressing a key oncogenic driver in pancreatic cancer.
Continued progress will depend on a strong and stable research ecosystem that enables translation of these discoveries from bench to bedside.
Join us in telling members of Congress to prioritize patients at.”
Other articles about Pancreatic Cancer on OncoDaily.